Gina Columbus

In an interview with CURE, Leena Gandhi, M.D., Ph.D., discussed emerging developments in the first-line treatment for patients with ALK-positive NSCLC, as well as novel agents emerging in the field.

The results of phase 3 FLAURA trial could potentially change the treatment paradigm for some patients with lung cancer.

Andre Goy, M.D., discusses some exciting advances in mantle cell lymphoma (MCL).

What role will immunotherapy play in the future treatment of GI cancers? CURE spoke to Brian Hemphill, M.D., to find out.

An ongoing trial studying Keytruda (pembrolizumab) with the first-in-class IDO1 inhibitor epacadostat (INCB024360) can mean drastic change for patients with melanoma.

Kiran K. Turaga explains that, even with all the advancements and novel treatments in melanoma, surgery is still critical.

In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.

Dr. Daniel H. Ahn, D.O., spoke with CURE about new advances in gastroesophageal cancers including immunotherapies and stemness inhibitors.

Researchers aim to improve patient outcomes by working on individualized metastatic colorectal cancer treatments.

Finola Hughes from TV's "General Hospital" and Ellen K. Ritchie, M.D. are teaming up to raise awareness for polycythemia vera.

2016 was an exciting year for non-small cell lung cancer, and more advances are expected for 2017.

The treatment landscape of triple-negative breast cancer is vastly changing. CURE spoke with Joyce A. O’Shaughnessy, M.D. about what to expect.

There have been exciting developments in the field of HER2-positive breast cancer.

A study being conducted at the MD Anderson Cancer Center is looking at whether certain patients with breast cancer can forgo surgery.

Jenny C. Chang, M.D., discusses the future of breast cancer care, and what role molecular testing will play.

After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.

Michael J. Mauro, M.D., discusses advances in treating myeloproliferative disorders.

New advancements are quickly advancing the treatment landscape of lung cancer.

Xofigo's role in the treatment of metastatic castration-resistant prostate cancer will continue to change.

Andrew D. Zelenetz, M.D., Ph.D. weighs in on recent research and the future of treating hematologic malignancies.

Stem cell transplant is still the only curative treatment option for many hematologic malignancies, even as novel drugs continue to emerge.

Liquid biopsies are quick, convenient and a crucial part of planning treatment for many patients with lung cancer, says Luis E. Raez, M.D.

Novel combinations may lead to the future of HR+ breast cancer care.

Mohammad Jahanzeb, M.D. discussed the challenges in treating non-driver lung adenocarcinoma.

Martin Dietrich, M.D., Ph.D., discusses testing for rarer genetic mutations in patients with lung cancer.

Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert Chung-Han (Joe) Lee, M.D., weighs in.

For patients with lung cancer that is limited in its spread, radiation may help. But exactly who should try it, and when?

As immunotherapy's potential continues to grow in the treatment of bladder cancer, Gopa Iyer, M.D., says that more research needs to be done before it becomes the next new standard.

For the first time in history, MPN guidelines have been set by the NCCN.

More advancements in lung cancer are bound to be made, says Edgardo S. Santos, M.D.